Xu H, Zhao X, Zhang P, Zhang Y, Zhou Q, Wu H
Heliyon. 2024; 10(20):e38336.
PMID: 39640769
PMC: 11619953.
DOI: 10.1016/j.heliyon.2024.e38336.
Gurbel P, Bliden K, Kundan P, Kraft D, Parekh R, Singh S
J Thromb Thrombolysis. 2023; 57(1):21-28.
PMID: 38066385
PMC: 10830588.
DOI: 10.1007/s11239-023-02914-7.
Dunster J, Wright J, Samani N, Goodall A
Front Cardiovasc Med. 2022; 9:919394.
PMID: 35845083
PMC: 9281867.
DOI: 10.3389/fcvm.2022.919394.
Gurbel P, Tantry U, Storey R
J Thromb Thrombolysis. 2021; 52(4):992-998.
PMID: 34021852
PMC: 8140326.
DOI: 10.1007/s11239-021-02465-9.
Cheng D, Zhao S, Hao Y
Biosci Rep. 2020; 40(7).
PMID: 32639536
PMC: 7364512.
DOI: 10.1042/BSR20201346.
microRNAs as promising biomarkers of platelet activity in antiplatelet therapy monitoring.
Krammer T, Mayr M, Hackl M
Int J Mol Sci. 2020; 21(10).
PMID: 32423125
PMC: 7278969.
DOI: 10.3390/ijms21103477.
Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Mshelbwala F, Hugenberg D, Kreutz R
J Thromb Thrombolysis. 2020; 50(3):619-627.
PMID: 32152791
DOI: 10.1007/s11239-020-02075-x.
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Pollack Jr C, Davoudi F, Diercks D, Becker R, James S, Lim S
Clin Cardiol. 2017; 40(6):390-398.
PMID: 28598510
PMC: 6490557.
DOI: 10.1002/clc.22733.
Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention.
Lu Y, Li Y, Yao R, Li Y, Li L, Zhao L
Exp Ther Med. 2016; 11(6):2177-2184.
PMID: 27284299
PMC: 4887760.
DOI: 10.3892/etm.2016.3224.
Novel antiplatelet agents in cardiovascular medicine.
Rafeedheen R, Bliden K, Liu F, Tantry U, Gurbel P
Curr Treat Options Cardiovasc Med. 2015; 17(6):383.
PMID: 25895737
DOI: 10.1007/s11936-015-0383-0.
G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
Gurbel P, Kuliopulos A, Tantry U
Arterioscler Thromb Vasc Biol. 2015; 35(3):500-12.
PMID: 25633316
PMC: 4836833.
DOI: 10.1161/ATVBAHA.114.303412.
Pharmacology of antiplatelet agents.
Kalra K, Franzese C, Gesheff M, Lev E, Pandya S, Bliden K
Curr Atheroscler Rep. 2013; 15(12):371.
PMID: 24142550
DOI: 10.1007/s11883-013-0371-3.
Circulating cells as predictors of secondary manifestations of cardiovascular disease: design of the CIRCULATING CELLS study.
Hoefer I, Sels J, Jukema J, Bergheanu S, Biessen E, McClellan E
Clin Res Cardiol. 2013; 102(11):847-56.
PMID: 23975238
DOI: 10.1007/s00392-013-0607-9.
The P2Y(12) receptor as a target of antithrombotic drugs.
OConnor S, Montalescot G, Collet J
Purinergic Signal. 2011; 7(3):325-32.
PMID: 21710143
PMC: 3166993.
DOI: 10.1007/s11302-011-9241-z.
Mean platelet volume and prevalence of peripheral artery disease, the National Health and Nutrition Examination Survey, 1999-2004.
Berger J, Eraso L, Xie D, Sha D, Mohler 3rd E
Atherosclerosis. 2010; 213(2):586-91.
PMID: 20940069
PMC: 3739454.
DOI: 10.1016/j.atherosclerosis.2010.09.010.
S-nitrosothiols as selective antithrombotic agents - possible mechanisms.
Gordge M, Xiao F
Br J Pharmacol. 2010; 159(8):1572-80.
PMID: 20233220
PMC: 2925480.
DOI: 10.1111/j.1476-5381.2010.00670.x.
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Iijima R, Ndrepepa G, Mehilli J, Neumann F, Schulz S, Berg J
Clin Res Cardiol. 2007; 97(3):160-8.
PMID: 18046527
DOI: 10.1007/s00392-007-0603-z.
Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.
Lau W, Gurbel P
Pharm Res. 2006; 23(12):2691-708.
PMID: 17061171
DOI: 10.1007/s11095-006-9084-4.